| MECP2 — Methyl-CpG Binding Protein 2 | |
|---|---|
| Symbol | MECP2 |
| Full Name | Methyl-CpG Binding Protein 2 |
| Chromosome | Xq28 |
| NCBI Gene | 4204 |
| Ensembl | ENSG00000169057 |
| OMIM | 300005 |
| UniProt | P51608 |
| Diseases | Rett Syndrome, MECP2 Duplication Syndrome |
| Expression | Cerebral cortex, Hippocampus, Cerebellum, Brainstem, Basal ganglia, Thalamus |
| Key Mutations | |
| p.R106W — missense, MBD domain p.R133C — missense, MBD domain p.T158M — missense (most common) p.R168X — nonsense, TRD domain p.R255X — nonsense, TRD domain |
|
Mecp2 — Methyl Cpg Binding Protein 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MECP2 (Methyl-CpG Binding Protein 2) is a gene located on the X chromosome at Xq28 that encodes a critical epigenetic regulator of gene expression in the nervous system [1].
Mutations in MECP2 are the primary cause of [Rett syndrome[/diseases/rett-syndrome, a severe neurodevelopmental disorder affecting approximately 1 in 10,000–15,000 live female births worldwide [2].
The gene was first identified as a cause of Rett syndrome in 1999 by Ruthie Amir and colleagues in Huda Zoghbi's laboratory at Baylor College of Medicine [1].
MECP2 is catalogued as NCBI Gene ID [4204] and OMIM [300005].
The MeCP2 protein functions as both a transcriptional repressor and activator, binding to methylated CpG dinucleotides across the genome.
It is one of the most abundant chromatin-associated proteins in mature [neurons[/entities/neurons, approaching the abundance of histones, with approximately one molecule per every two nucleosomes [3].
Loss-of-function mutations lead to widespread dysregulation of gene expression programs essential for [synaptic maturation], dendritic morphology, and neuronal circuit function.
Importantly, landmark studies have demonstrated that neurological deficits in Rett syndrome mouse models can be reversed by restoring MECP2 expression even in adult animals, providing strong rationale for therapeutic
gene replacement strategies [4].
The MECP2 gene spans approximately 76 kb of genomic DNA and contains four exons, producing two major splice isoforms: MeCP2-e1 (encoded by exons 1, 3, 4) and MeCP2-e2 (encoded by exons 1, 2, 3, 4) [5]. The MeCP2-e1 isoform is the predominant form in the brain and is preferentially affected in Rett syndrome.
The MeCP2 protein contains several functional domains:
The protein also undergoes extensive post-translational modifications including phosphorylation at multiple sites (S80, S229, S421, T308), which regulate its transcriptional activity in response to neuronal activity and signaling [5].
MeCP2 is a master epigenetic regulator that reads DNA methylation patterns and translates them into transcriptional outcomes.
In [neurons[/entities/neurons, MeCP2 binds broadly across the genome, preferentially at methylated CpG dinucleotides and non-CpG methylation sites (particularly mCA), which are highly abundant in mature [neurons[/entities/neurons [3].
Through its interaction with the NCoR/SMRT co-repressor complex, MeCP2 modulates [histone] deacetylation and chromatin compaction [6].
MeCP2 functions as both a transcriptional repressor and activator: it represses genes enriched in methylated cytosine residues while activating genes through interaction with CREB1 and other transcriptional activators. This dual role explains why loss of MeCP2 leads to bidirectional dysregulation of gene expression — some genes are aberrantly upregulated while others are downregulated [1].
MeCP2 is essential for the maturation and maintenance of [synapses] and neuronal circuits. Key roles include:
MeCP2 expression is ubiquitous but particularly high in the brain, where it increases dramatically during postnatal neuronal maturation. Key expression regions include:
Expression data is available from the Allen Human Brain Atlas.
[Rett syndrome[/diseases/rett-syndrome is caused by loss-of-function mutations in MECP2 and is one of the most common genetic causes of intellectual disability in females [1][2].
The disorder follows an X-linked dominant inheritance pattern; affected males typically do not survive to birth, while heterozygous females exhibit symptoms due to mosaic X-inactivation patterns.
Clinical features include:
Over 900 pathogenic MECP2 mutations have been identified, but eight common mutations account for approximately 70% of all Rett syndrome cases: R106W, R133C, T158M, R168X, R255X, R270X, R294X, and R306C [2][5].
Genomic duplications encompassing MECP2 cause a distinct syndrome predominantly affecting males, characterized by severe intellectual disability, infantile hypotonia, progressive [spasticity], epilepsy, recurrent respiratory infections, and premature death [7]. This syndrome demonstrates that both too little and too much MeCP2 protein is detrimental to neuronal function.
Gene replacement therapy using adeno-associated viral (AAV) vectors to deliver functional MECP2 copies is a leading therapeutic strategy.
Multiple clinical trials are underway as of 2025, building on preclinical demonstrations that MeCP2 restoration can reverse neurological deficits in adult Rett syndrome mouse models [4][9].
Key challenges include achieving appropriate expression levels (avoiding both under- and over-expression) and broad CNS distribution.
Since Rett syndrome females carry one normal copy of MECP2 on their inactive X chromosome, therapeutic strategies to selectively reactivate this silenced copy represent an attractive approach. Several groups are investigating small molecules and antisense oligonucleotides targeting XIST or other regulators of X-inactivation [5].
The study of Mecp2 — Methyl Cpg Binding Protein 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.